Clinical Trial Update: Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis [Phase 2]

View source ↗

Summary

Phase 2 trial update on SAR156597 for idiopathic pulmonary fibrosis reports efficacy and safety data post-completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• SAR156597

Snippet

Sponsor: Sanofi | Conditions: Idiopathic Pulmonary Fibrosis | Phase 2 | Status: COMPLETED | Results posted: 2020-05-26